Anti-tumor Immunity against CT26 Colon Tumor in Mice Immunized with Plasmid DNA Encoding β-Galactosidase Fused to an Envelope Protein of Endogenous Retrovirus

Author： Takeda J. Sato Y. Kiyosawa H. Mori T. Yokoya S. Irisawa A. Miyata M. Obara K. Fujita T. Suzuki T. Kasukawa R. Wanaka A.

Publisher： Academic Press

ISSN： 0008-8749

Source： Cellular Immunology, Vol.204, Iss.1, 2000-08, pp. : 11-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Endogenous retroviral gene products have been recognized as being expressed in human cancerous tissues. However, these products have not been shown to be antigenic targets for T-cells, possibly due to immune tolerance. Since carcinogen-induced colon tumor CT26 expresses an envelope protein, gp70, of an endogenous ecotropic murine leukemia virus that is comparable to human tumor-associated antigens, we examined whether a DNA vaccine containing the gp70 gene induces protective immunity against CT26 cells. Injection of mice with plasmid DNA (pDNA) encoding gp70 alone failed to induce anti-gp70 antibody (Ab) or anti-CT26 cytotoxic T lymphocyte (CTL) responses. However, immunization with pDNA encoding the β-galactosidase (β-gal)/gp70 fusion protein induced anti-gp70 Ab and anti-CT26 CTL responses and conferred protective immunity against CT26 cells. These results indicate that β-gal acts as an immunogenic carrier protein that helps in the induction of immune responses against the poorly immunogenic gp70. Considering these results, it is possible that potential tolerance to the endogenous retroviral gene products expressed by human tumors may be overcome by DNA vaccines that contain an endogenous retroviral gene fused to genes encoding immunogenic carrier proteins.